IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation

Journal of Clinical Investigation

Volumn 118, Issue 2, 2008, Pages 597-607

  Ma, Hak Ling ^a   Liang, Spencer ^a   Li, Jing ^a   Napierata, Lee ^a   Brown, Tom ^a   Benoit, Stephen ^a   Senices, Mayra ^a   Gill, Davinder ^a   Dunussi Joannopoulos, Kyriaki ^a   Collins, Mary ^a   Nickerson Nutter, Cheryl ^a   Fouser, Lynette A ^a   Young, Deborah A ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 12; INTERLEUKIN 22; INTERLEUKIN 23; MESSENGER RNA; NEUTRALIZING ANTIBODY; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEIN P40;

ACANTHOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE EXPRESSION; HELPER CELL; KERATINOCYTE; MOUSE; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PSORIASIS; SCID MOUSE; SENSITIVITY ANALYSIS; SKIN INFLAMMATION; STATISTICAL SIGNIFICANCE; TH17 CELLS;

ANIMALS; ANTIBODIES, BLOCKING; CYTOKINES; DERMATITIS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; INTERLEUKIN-12; INTERLEUKIN-12 SUBUNIT P40; INTERLEUKIN-17; INTERLEUKINS; LIPOPOLYSACCHARIDES; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED BALB C; PSORIASIS; SKIN; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY;

EID: 38849187386     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI33263     Document Type: Article

References (42)

1. Schon, M.P., and Boehncke, W.H. 2005. Psoriasis. N. Engl. J. Med. 352:1899-1912.
2. Zenz, R., et al. 2005. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature. 437:369-375.
3. Cook, P.W., Brown, J.R., Cornell, K.A., and Pittelkow, M.R. 2004. Suprabasal expression of human amphiregulin in the epidermis of transgenic mice induces a severe, early-onset, psoriasis-like skin pathology: Expression of amphiregulin in the basal epidermis is also associated with synovitis. Exp. Dermatol. 13:347-356.
4. Lowes, M.A., Bowcock, A.M., and Krueger, J.G. 2007. Pathogenesis and therapy of psoriasis. Nature. 445:866-873.
5. Groves, R.W., et al. 1996. Inflammatory and hyperproliferative skin disease in mice that express elevated levels of the IL-1 receptor (Type I) on epidermal keratinocytes. Evidence that IL-1-inducible secondary cytokines produced by keratinocytes in vivo can cause skin disease. J. Clin. Invest. 98:336-344.
6. Xia, Y.-P., et al. 2003. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood. 102:161-168.
7. Hong, K., Chu, A., Ludviksson, B.R., Berg, E.L., and Ehrhardt, R.O. 1999. IL-12, independently of IFN-{gamma}, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J. Immunol. 162:7480-7491.
8. Chan, J.R., et al. 2006. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J. Exp. Med. 203:2577-2587.
9. Zheng, Y., et al. 2007. Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 445:648-651.
10. McKenzie, B.S., Kastelein, R.A., and Cua, D.J. 2006. Understanding the IL-23-IL-17 immune pathway. Trends Immunol. 27:17-23.
11. Harrington, L.E., et al. 2005. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6:1123-1132.
12. Park, H., et al. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6:1133-1141.
13. Liang, S.C., et al. 2006. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 203:2271-2279.
14. Wolk, K., et al. 2004. IL-22 increases the innate immunity of tissues. Immunity. 21:241-254.
15. Boniface, K., et al. 2005. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J. Immunol. 174:3695-3702.
16. Wolk, K., et al. 2006. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur. J. Immunol. 36:1309-1323.
17. Schon, M.P., Detmar, M., and Parker, C.M. 1997. Murine psoriasis-like disorder induced by naive CD4+ T cells. Nat. Med. 3:183-188.
18. Dejaco, C., Duftner, C., Grubeck-Loebenstein, B., and Schirmer, M. 2006. Imbalance of regulatory T cells in human autoimmune diseases. Immunology. 117:289-300.
19. Sakaguchi, S., Setoguchi, R., Yagi, H., and Nomura, T. 2006. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in self-tolerance and autoimmune disease. Curr. Top. Microbiol. Immunol. 305:51-66.
20. Gottlieb, A.B., Luster, A.D., Posnett, D.N., and Carter, D.M. 1988. Detection of a gamma interferon-induced protein IP-10 in psoriatic plaques. J. Exp. Med. 168:941-948.
21. Gottlieb, A.B., et al. 2005. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J. Immunol. 175:2721-2729.
22. Arican, O., Aral, M., Sasmaz, S., and Ciragil, P. 2005. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005:273-279.
23. Wolk, K., and Sabat, R. 2006. Interleukin-22: A novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev. 17:367-380.
24. Charles, P., et al. 1999. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-{alpha} therapy in rheumatoid arthritis. J. Immunol. 163:1521-1528.
25. Austin, L.M., Ozawa, M., Kikuchi, T., Walters, I.B., and Krueger, J.G. 1999. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest. Dermatol. 113:752-759.
26. Chang, J.C.C., et al. 1994. CD8+ T cells in psoriatic lesions preferentially use T-cell receptor V{beta}3 and/or V{beta}13.1 genes. Proc. Natl. Acad. Sci. U. S. A. 91:9282-9286.
27. Gudjonsson, J.E., Johnston, A., Dyson, M., Valdimarsson, H., and Elder, J.T. 2007. Mouse models of psoriasis. J. Invest. Dermatol. 127:1292-1308.
28. Kim, J.M., Rasmussen, J.P., and Rudensky, A.Y. 2007. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8:191-197.
29. Chen, W., et al. 2003. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-{beta} induction of transcription factor Foxp3. J. Exp. Med. 198:1875-1886.
30. Langrish, C.L., et al. 2004. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol. Rev. 202:96-105.
31. Muhl, H., and Pfeilschifter, J. 2003. Anti-inflammatory properties of pro-inflammatory interferon-[gamma]. Int. Immunopharmacol. 3:1247-1255.
32. Willenborg, D.O., Fordham, S.A., Staykova, M.A., Ramshaw, I.A., and Cowden, W.B. 1999. IFN-{gamma} is critical to the control of murine autoimmune encephalomyelitis and regulates both in the periphery and in the target tissue: a possible role for nitric oxide. J. Immunol. 163:5278-5286.
33. Kauffman, C.L., et al. 2004. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J. Investig. Dermatol. 123:1037-1044.
34. Krueger, G.G., et al. 2007. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 356:580-592.
35. Chaudhari, U., et al. 2001. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 357:1842-1847.
36. Toichi, E., et al. 2006. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J. Immunol. 177:4917-4926.
37. Cameron, A., Kirby, B., Fei, W., and Griffiths, C. 2002. Natural killer and natural killer-T cells in psoriasis. Arch. Dermatol. Res. 294:363-369.
38. Sano, S., et al. 2005. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat. Med. 11:43-49.
39. McMahon, E.J., Bailey, S.L., Castenada, C.V., Waldner, H., and Miller, S.D. 2005. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat. Med. 11:335-339.
40. Braff, M.H., Bardan, A., Nizet, V., and Gallo, R.L. 2005. Cutaneous defense mechanisms by antimicrobial peptides. J. Invest. Dermatol. 125:9-13.
41. Braff, M.H., and Gallo, R.L. 2006. Antimicrobial peptides: an essential component of the skin defensive barrier. Curr. Top. Microbiol. Immunol. 306:91-110.
42. Li, J., et al. 2004. Temporal associations between interleukin 22 and the extracellular domains of IL-22R and IL-10R2. Int. Immunopharmacol. 4:693-708.